Following a comprehensive patient examination, including the assessment of periodontal and peri-implant diseases as well as considering the patient's needs, a pretherapeutic prognosis for each tooth and implant is given.
Teeth and implants with a secure pretherapeutic prognosis require simple procedures and may be regarded as secure abutments for function and with a doubtful pretherapeutic prognosis usually need a comprehensive therapy. Such teeth and implants must be brought into the category with a secure prognosis by means of additional therapy such as endodontic, restorative, and surgical procedures.
Teeth and implants with a hopeless pretherapeutic prognosis should be extracted/explanted during the initial phase of cause-related therapy (i.e., infection control). For example, teeth with vertical root fracture or unrestorable caries and implants with mobility or unrestorable malposition fall into the category of hopeless units. The primary goal of periodontal and peri-implant therapy should be to arrest disease progression. The latest consensus statement highlights that periodontitis can be successfully controlled and treated teeth can be retained for life.
Nevertheless, for patients with uncontrolled contributing factors, the endpoints might not always be achievable, and low disease activity may be an acceptable therapeutic goal. Similarly, the management of peri-implantitis frequently requires surgical intervention following nonsurgical therapy due to incomplete treatment outcomes.
Different surgical modalities can be effective and lead to significant improvement; however, achieving complete resolution of peri-implantitis is challenging, not always predictable, and can depend on multiple baseline factors. Therefore, this review aims at summarising available evidence on the rationale for incorporating systemic, lifestyle-related, clinical, and radiographic prognostic factors into treatment planning of patients diagnosed with periodontal and peri-implant diseases.
Authors: Anastasiya Orishko, Jean-Claude Imber, Andrea Roccuzzo, Alexandra Stähli, Giovanni E. Salvi
Source: https://onlinelibrary.wiley.com/
TheraBreath, the #1 alcohol-free mouthwash brand in the U.S.*, has introduced a new line of dentist-formulated, clinically tested toothpastes designed to support professional oral care...
A systematic review was conducted to examine the evidence for the effectiveness and safety of corticotomy-facilitated orthodontics.
Editorials 09 September 2025
The news is out of the tube! In response to increasing demand from the millions of fans of its TikTok-viral rinses, TheraBreath—the revolutionary oral care brand that fights bad breath at its...
News 01 September 2025
In recognition of National Tooth Fairy Day on August 22, Delta Dental released additional findings from its 2025 Original Tooth Fairy Poll.
Editorials 25 August 2025
Dr. Joshua Emrick’s Team Sheds New Light on Protective Tooth Nerve Function in Cell Reports Study
Joshua J. Emrick, DDS, PhD, assistant professor in the Department of Biologic and Materials Sciences & Prosthodontics (BMSP), shines a spotlight on the sensory neurons in teeth in a recent...
Implantology 17 October 2025
To investigate whether cross-section imaging influences the planning and therapy of standard implant cases in the posterior mandible.
Editorials 17 October 2025
In her new role she is providing direction and supporting initiatives that elevating UFCD's translational research agenda.
Products 17 October 2025
Presto Dental, a new brand affiliated with the Abra Health Group, proudly announces the grand opening of its flagship Connecticut location in Bridgeport. This state-of-the-art.
News 17 October 2025
The American Association of Oral and Maxillofacial Surgeons (AAOMS) celebrated the achievements of more than 30 individuals at the association’s 107th Annual Meeting, Scientific Sessions and...
Phenom, an applied AI company that helps organizations hire faster, develop better, and retain longer, announced The Aspen Group (TAG) earned the Brandon.